Related Experiment Videos
Neutralization of HIV-1
H Golding1, M P D'Souza, J Bradac
1Laboratory of Retrovirus Research, FDA/CBER, Bethesda, Maryland 20892.
Insights
Researchers convened to standardize HIV-1 neutralization assays for vaccine development. The workshop focused on identifying key assays and reagents to evaluate the efficacy of prophylactic vaccines in clinical trials.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- The development of effective Human Immunodeficiency Virus type 1 (HIV-1) prophylactic vaccines is a global health priority.
- Standardized methods are crucial for evaluating vaccine efficacy in clinical trials.
- Existing neutralization and binding assays for immune sera require critical assessment and standardization.
Abstract:
A Workshop on Neutralization of HIV-1: Technology and reagents for analysis of prophylactic vaccines clinical trials, sponsored by the Food and Drug Administration (FDA) and the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), was held on April 19-20, 1993, in Bethesda, Maryland. This workshop brought together researchers who are involved in the development, testing, and evaluation of HIV-1 prophylactic vaccines. The major objectives were (1) to discuss critically the different neutralization and binding assays that are currently used in the evaluation of immune sera; (2) to identify assays that will measure the "most relevant" antibodies, which are likely to predict neutralization of primary isolates; and (3) to identify well-characterized reference reagents, which could be used to standardize neutralization assays used in laboratories around the world.